Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride and dutasteride can affect sexual function in BPH patients.

This study found that terazosin hydrochloride, when used with finasteride, improved prostate volume and lowered blood pressure in BPH patients with high blood pressure, although the overall treatment effect was not significantly different from controls.

This study investigates the potential influence of genetic variations in the 5α-reductase type 2 gene on the effectiveness of finasteride treatment for benign prostatic hyperplasia, but it reports no new clinical results.

Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.

This study suggested that long-term finasteride treatment for BPH patients may induce neuroendocrine activity in the prostate, potentially increasing the risk of developing aggressive prostate cancer.

This study found that combining tamsulosin with finasteride was the most cost-effective treatment for mild to moderate BPH among the regimens tested.

Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

This study observed improvements in hair loss, acne, and BPH symptoms after addressing vitamin D and progesterone deficiencies in male patients, suggesting the potential benefits of this therapeutic approach.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.

This study found that prescribing finasteride for two weeks before TURP surgery reduces intraoperative and postoperative blood loss, the rate of blood transfusion, and irrigation fluid usage in patients with BPH.

This study found that UV-B exposure significantly increased the expression of inflammatory cytokines IL-1β and IL-8 in cultured sebocytes.

This study found that activin B promotes the initiation and development of hair follicles in both cultured and neonatal mouse skin models.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This commentary discusses the public health implications of benign prostatic hyperplasia (BPH) and provides no new research results.

This study found that a 22-bp InDel polymorphism in the FGF7 gene was significantly associated with growth traits in goats, with genotypes ID and/or II linked to better growth compared to genotype DD, indicating its potential as a molecular marker in breeding programs.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

In this study, researchers found that exosomes derived from Pinctada martensii mucus can effectively inhibit melanin production in melanoma cells and zebrafish without adverse effects, potentially offering a promising therapeutic strategy for treating pigmentary disorders by modulating the NF-κB signaling pathway.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

This study identified a 195 bp duplication in crested chickens that causes large crest feathers and can be associated with cerebral hernia in some breeds, but not all.

This editorial examines the use of multiple drugs for treating lower urinary tract symptoms due to benign prostatic hyperplasia but offers no new research findings.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

This study found that family caregivers reported significantly longer sleep onset latency compared to carefully matched non-caregiving controls, with depressive symptoms predicting poorer sleep quality among caregivers.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

This update provides information on new drug approvals but does not offer new clinical research findings.